Brooks Laboratories Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Brooks Laboratories Ltd is ₹ 56.48 as of 30 Apr 15:30 . The P/E Ratio of Brooks Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Brooks Laboratories Ltd changed from ₹ 153.53 crore on March 2021 to ₹ 317.37 crore on March 2025 . This represents a CAGR of 15.63% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Brooks Laboratories Ltd for the Dec '25 is ₹ 21.89 crore as compare to the Sep '25 revenue of ₹ 29.58 crore. This represent the decline of -26% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Brooks Laboratories Ltd for the Dec '25 is ₹ 6.05 crore as compare to the Sep '25 ebitda of ₹ 8.65 crore. This represent the decline of -30.06% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Brooks Laboratories Ltd changed from ₹ -2.41 crore to ₹ 5.5 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Brooks Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Brooks Laboratories Ltd

Brooks Laboratories Limited was incorporated on January 23, 2002.
The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment.
It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes.
At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Brooks Laboratories Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Brooks Laboratories Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Brooks Laboratories Ltd is 166 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 67,884 Cr

What are the key factors driving the stock performance of Brooks Laboratories Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Brooks Laboratories Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Brooks Laboratories Ltd and Glenmark Pharmaceuticals Ltd?

As of May 3, 2026, the Brooks Laboratories Ltd stock price is INR ₹56.48. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2405.55.

How do dividend payouts of Brooks Laboratories Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Brooks Laboratories Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.